2,925 Shares in Natera, Inc. $NTRA Acquired by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,925 shares of the medical research company’s stock, valued at approximately $471,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. JPMorgan Chase & Co. boosted its position in shares of Natera by 44.3% during the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after buying an additional 3,263,822 shares during the last quarter. Norges Bank bought a new position in Natera during the 2nd quarter valued at about $277,749,000. AQR Capital Management LLC boosted its holdings in shares of Natera by 44.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,726,750 shares of the medical research company’s stock valued at $291,717,000 after acquiring an additional 532,769 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Natera by 20.6% in the second quarter. Franklin Resources Inc. now owns 1,937,647 shares of the medical research company’s stock worth $327,346,000 after acquiring an additional 330,696 shares during the period. Finally, Holocene Advisors LP raised its holdings in shares of Natera by 118.3% during the second quarter. Holocene Advisors LP now owns 572,832 shares of the medical research company’s stock valued at $96,774,000 after purchasing an additional 310,452 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Activity

In related news, insider Solomon Moshkevich sold 23,205 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70. Following the completion of the transaction, the insider directly owned 144,992 shares of the company’s stock, valued at approximately $34,035,422.08. This trade represents a 13.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Roelof Botha sold 75,000 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $236.12, for a total transaction of $17,709,000.00. Following the sale, the director directly owned 1,154,198 shares in the company, valued at approximately $272,529,231.76. The trade was a 6.10% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 455,899 shares of company stock worth $106,475,440. 5.63% of the stock is owned by corporate insiders.

Natera Trading Down 2.2%

Shares of NTRA stock opened at $207.84 on Friday. The stock has a market capitalization of $28.75 billion, a price-to-earnings ratio of -90.76 and a beta of 1.64. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36. The stock’s 50-day moving average price is $231.14 and its 200-day moving average price is $198.16.

Analyst Ratings Changes

Several brokerages recently issued reports on NTRA. BTIG Research raised their target price on shares of Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Guggenheim increased their price target on Natera from $230.00 to $270.00 and gave the company a “buy” rating in a report on Monday, January 5th. Evercore lifted their price objective on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Wells Fargo & Company upped their price objective on Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. Finally, Citigroup started coverage on Natera in a research report on Wednesday, January 7th. They issued a “buy” rating and a $300.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $249.20.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.